GLP-1RAs are gaining importance as a pillar of the therapeutic strategies in patients with cardiovascular-kidney-metabolic syndrome.2 Indeed, a large body of evidence has shown their role in reducing myocardial fibrosis and cardiac hypertrophy, improving cardiac function and attenuating cardiometabolic dysregulation.3 In addition, GLP-1RAs have been successfully tested in the pharmacological management of overweight and obesity.4 A significant reduction of MACE in subjects treated with GLP-1RAs has been demonstrated in different clinical settings.
Weekly Journal Scan: effects of oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes and high risk profile / Gallo, Giovanna; Volpe, Massimo. - In: EUROPEAN HEART JOURNAL. - ISSN 1522-9645. - 46:29(2025), pp. 2934-2936. [10.1093/eurheartj/ehaf299]
Weekly Journal Scan: effects of oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes and high risk profile
Gallo, Giovanna;Volpe, Massimo
2025
Abstract
GLP-1RAs are gaining importance as a pillar of the therapeutic strategies in patients with cardiovascular-kidney-metabolic syndrome.2 Indeed, a large body of evidence has shown their role in reducing myocardial fibrosis and cardiac hypertrophy, improving cardiac function and attenuating cardiometabolic dysregulation.3 In addition, GLP-1RAs have been successfully tested in the pharmacological management of overweight and obesity.4 A significant reduction of MACE in subjects treated with GLP-1RAs has been demonstrated in different clinical settings.| File | Dimensione | Formato | |
|---|---|---|---|
|
Gallo_Weekly_2025.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
153.45 kB
Formato
Adobe PDF
|
153.45 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
